XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B

Submitted by admin on December 7, 2019 - 11:55pm
Source: 
Seeking Alpha
News Tags: 
Xbiotech
JNJ
Janssen
bermekimab
Headline: 
XBiotech out-licenses anti-inflammatory antibody to Janssen for up to $1.35B
snippet: 

XBiotech (NASDAQ:XBIT) inks an agreement with Johnson & Johnson (NYSE:JNJ) unit Janssen Biotech for global rights to anti-inflammatory candidate bermekimab.

Do Not Allow Advertisers to Use My Personal information